IMMUNOME INC (IMNM)
Sector: Health Care
2026 Annual Meeting Analysis
IMMUNOME INC · Meeting: June 9, 2026
Directors FOR
3
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Class III Directors
Boylan joined the board in October 2023 (within 24 months of the meeting), so he is exempt from the TSR trigger; he brings relevant biotech investment banking and venture capital expertise, holds no disqualifying board seats, and attended all required meetings.
Wagenheim has served since 2017 and the TSR trigger does not apply because IMNM's 3-year return of +343.7% is strongly positive and outperforms XBI (SPDR S&P Biotech ETF) by +276.2 percentage points, far exceeding the 65-percentage-point threshold required to trigger a negative vote; he brings relevant venture capital and life sciences experience and met the 75% attendance requirement.
Swain joined the board in April 2024 (within 24 months of the meeting), so she is exempt from the TSR trigger; her oncology research and clinical trial background is highly relevant to IMNM's drug development stage, she serves on the audit committee with appropriate medical and scientific expertise, and she attended all required meetings.
All three Class III nominees pass the policy screens — the two newer directors (Boylan, Swain) are within the 24-month exemption window, and the longest-tenured nominee (Wagenheim) benefits from exceptional stock outperformance versus XBI (SPDR S&P Biotech ETF) that is far above the trigger threshold. No overboarding, attendance, independence, or qualifications concerns were identified.
Say on Pay
✓ FORCEO
Clay Siegall, Ph.D.
Total Comp
$7,682,601
Prior Support
N/A
CEO total compensation of approximately $7.7 million is reasonable for a biotech company of IMNM's size and stage ($2.7B market cap), with a substantial majority delivered through stock options that only have value if the share price rises — directly aligning the CEO's interests with shareholders. The company's stock more than doubled in 2025 and has returned +343.7% over three years, far outpacing the XBI (SPDR S&P Biotech ETF) benchmark, demonstrating strong pay-for-performance alignment. Annual cash bonuses were paid at 145–150% of target, which is above-target but supported by documented achievements including positive Phase 3 clinical data, manufacturing milestones, and multiple pipeline advances that represent genuine shareholder value creation.
Auditor Ratification
✓ FORAuditor
Ernst & Young LLP
Tenure
4 yrs
Audit Fees
$825,626
Non-Audit Fees
$0
Ernst & Young has audited IMNM since 2022 (approximately 4 years), well below the 25-year tenure threshold; non-audit fees were zero in 2025, so the non-audit fee ratio is 0%, far below the 50% concern level; the firm is a Big 4 auditor appropriate for a company of IMNM's size and complexity; no material restatements were disclosed.
Overall Assessment
The 2026 IMNM annual meeting presents a clean ballot with no significant governance concerns: all three director nominees pass policy screens, Ernst & Young receives a straightforward ratification given zero non-audit fees and short tenure, and the executive compensation program earns support on the strength of exceptional stock performance (+343.7% over three years vs. XBI — SPDR S&P Biotech ETF) and a pay structure where the majority of compensation is performance-linked equity. There are no stockholder-submitted proposals on the ballot.